Chaja Jacobs, medical oncologist in training, Amsterdam UMC
Geboren en getogen in Amsterdam, begon Chaja in 2011 aan de studie geneeskunde aan de VU. De interesse voor oncologie die zij tijdens haar eindexamenjaar al voelde, ontwikkelde zich in een passie voor de oncologische patiëntenzorg. Na het afronden van haar studie werkte zij een jaar als ANIOS Interne Geneeskunde in Zaandam, waarna ze in het Antoni van Leeuwenhoek intensief betrokken raakte bij de borstkankerzorg.
Momenteel werkt zij aan een promotie traject in het AMC en zet zij zich in voor de rechten van ANIOS/arts-onderzoekers via actief lidmaatschap bij De Jonge Specialist. Na afronding van haar promotie hoopt zij de opleiding tot internist te gaan volgen.
Marc Lobbes, radiation oncologist, MUMC+
Marc Lobbes is sinds 2011 mammaradioloog, met als specifieke aandachtsgebieden de toepassing van contrast-versterkte mammografie, de toepassing van kunstmatige intelligentie binnen de mammaradiologie en de evaluatie van okselkliermetastase middels (PET)MRI. Dr. Lobbes is tevens lid van de wetenschappelijke adviesraden van het LRCB en NABON/BOOG, alsook de opleidingscommissie van de European Society of Breast Imaging. Dr. Lobbes is auteur van meer dan honderd wetenschappelijke publicaties en boekhoofdstukken.
Anna Weiss, assistant professor of surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, USA
Dr. Anna Weiss completed her undergraduate and medical school training at Case Western Reserve University and her General Surgery Residency at the University of California, San Diego. She then completed her Breast Surgical Oncology Fellowship at the University of Texas MD Anderson Cancer Center.
Dr. Weiss is now a Breast Surgeon at Dana-Farber/Brigham and Women’s Cancer Center, Director of Breast Surgery Research at Dana-Farber/Brigham and Women’s Cancer Center South Shore, Assistant Professor of Surgery at Harvard Medical School, and an Executive Officer for the Alliance for clinical trials in oncology.
Her current research interests include surgical management of patients at hereditary increased risk for breast cancer and subtype-specific surgical management of the axilla.
John Martens, basic researcher, Erasmus MC
Prof. dr. Martens heads the laboratory of Translational Cancer Genomics at the department of Medical Oncology. He graduated (1988) and received his PhD (1994) in Molecular Biology at Wageningen University (NL). After 2 post-docs in Molecular Endocrinology, he proceeded his career from 2001 onwards in translational cancer genomics research at his current department where he became full professor on this topic in 2017. His research group consists of 20 employees and has a well-recognized track record in high-throughput genomics research. It is his ambition to discover and validate prognostic and predictive markers for breast cancer. In addition, to understand the evolution of metastatic cancer towards therapy resistance, he studies during treatment the temporal variation of biomarkers in the circulation (CTCs, CECs, ctDNA and exosomes). These research lines complemented with mechanistic in vitro research in breast cancer cell line models provide insight into molecular mechanisms of disease progression and therapy failure and help to offer the best treatment possible for our patients suffering from breast cancer.
Marleen Kok, medical oncologist,, NKI-AvL
Marleen Kok is sinds 2016 staflid in het Antoni van Leeuwenhoek en focust als medisch oncoloog op de behandeling en verbetering van de behandeling van borstkankerpatienten. Ze deed in 2015 haar post-doc Cancer Immunology bij Johns Hopkins University, USA. Sinds 2018 is ze groepsleider borstkanker immunotherapie bij het Nederlands Kanker Instituut (NKI) waar haar onderzoeksgroep zich bezig houdt met translationele studies naar het immuunsysteem van borstkankerpatienten. Ze leidt diverse klinische studies gericht op combinatie immunotherapie in de gemetastaseerde setting maar ook in de neoadjuvante setting. Marleen Kok is lid van de Scientific Committee van ESMO en ESMO Breast Cancer en ESMO faculty Tumor Immunology.
Janine Simons, radiation oncology resident, Erasmus MC
Janine Simons coördineerde de RISAS studie, waarin de accuratesse van de MARI-procedure gecombineerd met de schildwachtklierprocedure werd onderzocht. Op het afgelopen San Antonio borstkanker symposium zijn de resultaten gepresenteerd. Momenteel is zij in opleiding tot radiotherapeut-oncoloog in het Erasmus MC en als post-doc onderzoeker betrokken bij de MINIMAX studie.
Duncan Wheatley, Director of Research and Innovation Cornwall, Royal Hospitals Cornwall, UK
Duncan Wheatley is a Clinical Oncology Consultant at the Royal Cornwall Hospital Cancer Centre in Truro in 2002. He specialises in Breast and Urological tumours. He has been the Clinical Lead for cancer research in the very successful Peninsula area for many years, sits on the NCRI Breast Clinical Studies Group and is R&D Director at the Royal Cornwall Hospital. He is also an Honorary Senior Lecturer at Exeter University. He has been Chief Investigator and Principal Investigator on many studies and recruits all willing patients into as many studies as possible. He sits on the TMG for many studies and Chief clinical coordinator the FAST Forward and FAST studies. He is the Radiotherapy clinical lead for the recruiting ATNEC study.
Michael Gnant, professor of Surgery, Medical University of Vienna, Austria
Dr Michael Gnant is Full Professor of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast & Colorectal Cancer Study Group. He is co-chairing the renowned St Gallen Consensus Panel for Early Breast Cancer since 2015. Dr Gnant graduated in medicine in Vienna (1988) and subsequently specialized in surgery (1994) and surgical oncology. He also worked as a Visiting Scientist at the National Cancer Institute, National Institutes of Health, Bethesda, USA (1997–1999). Dr Gnant’s research interests include several fields of surgical oncology, in particular breast and pancreatic cancer, immunotherapy, bone-targeted treatment for tumor micrometastases, tumor dormancy/quiescence and late relapse, and pathwaydirected therapies such as mTOR and CDK4/6 inhibition, and he has been the
Principal Investigator of many (N>30) clinical trials in these fields. The author of more than 490 original peer-reviewed papers with an impact factor of 3,800 and an h-index of 69, Dr Gnant has presented over 1,000 lectures at national and international meetings. He is the recipient of multiple awards including the prestigious Claudia von Schilling Prize from the Medical University of Hannover, and a Corresponding Member of the Austrian Academy of Sciences. Dr Gnant is involved in many scientific societies including ASCO, AACR, ACS, Breast International Group (BIG), EORTC, ESSO, EUSOMA and UICC. He served as an executive board member of BIG, is an independent reviewer and IDMC member for the EORTC, UICC and other international bodies, and is a scientific reviewer and process evaluator for the European Union. Dr Gnant is also Editor-in-Chief of BREAST CARE, and editorial board member and reviewer for many top-tier peer-reviewed journals including The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, and Annals of Oncology.
Gabe Sonke, medical oncologist, NKI-AvL
Gabe Sonke is head of the Department of Medical Oncology at the Netherlands Cancer Institute and professor of Clinical Oncology at the University of Amsterdam, the Netherlands. He is a member of several oncology societies, including ASCO, ESMO, and EORTC. Additionally, he serves as a board member on the Dutch Medicines Evaluation Board and the Centre for Personalized Cancer Treatment. Professor Sonke has presented at many symposia and scientific meetings. His research interests include optimal use of anti-HER2 targeting agents and CDK4/6 inhibitors in breast cancer and intraperitoneal treatment and PARP inhibition in ovarian cancer. His research has been published in more than 170 articles in peer-reviewed journals.